Previous 10 | Next 10 |
Phase 2 SPiReL study of DPX-Survivac combination regimen with Keytruda® in r/r DLBCL successfully reached primary efficacy endpoint with 64% (7/11) of evaluable patients demonstrating a clinical response Translational and updated clinical response data from Phase 2 DeCidE1 st...
IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including COVID-19, today announced that it has completed its ...
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including COVID-19, announced today that it will hold a co...
IMV (NASDAQ: IMV ) announces the private placement of ~7.8M Units at C$2.86 per unit to a group of investors co-led by Fonds de Solidarité FTQ (C$7.5M) and Altium Capital. More news on: IMV Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Vaccine Candidate to Prevent COVID-19: Fonds de solidarité FTQ to Invest $7.5 Million in IMV Canada NewsWire QUÉBEC CITY, April 30, 2020 QUÉBEC CITY, April 30, 2020 /CNW Telbec/ - The Fonds de solidarité FTQ (the "Fonds" will invest $7.5 mi...
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced its intention to complete a private placement (the “Private Placement”) of 7,797,203 units of the Company (each, a “Unit”) at the market price of Cdn$2.86 per Unit based o...
IMV Inc. (Nasdaq: IMV; TSX: IMV) a clinical-stage biopharmaceutical company, today announced that Company’s management will be participating in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference on April 23, 2020 from 12pm-5pm ET. The conference will showcas...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
IMV, Inc. (IMV) Q4 2019 Results Earnings Conference Call March 31, 2020, 08:00 AM ET Company Participants Pierre Labbé - Chief Financial Officer Frederic Ors - Chief Executive Officer Joanne Schindler - Chief Medical Officer Marianne Stanford - Vice President, Research and...
Launched development program for a DPX-based vaccine candidate against COVID-19 Reported updated Phase 2 data from DeCidE1 study in advanced ovarian cancer; These encouraging results support DPX-Survivac being amongst the first in vivo T cell therapy to demonstrate meaningful cli...
News, Short Squeeze, Breakout and More Instantly...
GAAP Net Income of $8.3 million or $0.25 per diluted share Non-GAAP Net Income of $11.0 million or $0.33 per diluted share Declares Third Consecutive Quarterly Dividend Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, to...
IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire - First Quarter 2023 Net Investment Income per Share of $0.46 ; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to ...